A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin

SIMPLE SUMMARY: Carboplatin and paclitaxel constitute first-line treatment for ovarian cancer, producing tumor shrinkage in 70% of patients, but curing less than 20% with advanced stage disease. Previous studies have shown that treatment with ARN-3261, a small molecule inhibitor of the enzyme salt-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Dengxuan, Yang, Hailing, Mao, Weiqun, Rask, Philip J., Pang, Lan, Xu, Congjian, Vankayalapat, Hariprasad, Ahmed, Ahmed A., Bast, Robert C., Lu, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865895/
https://www.ncbi.nlm.nih.gov/pubmed/33503955
http://dx.doi.org/10.3390/cancers13030446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865895/
https://www.ncbi.nlm.nih.gov/pubmed/33503955
http://dx.doi.org/10.3390/cancers13030446

Ejemplares similares